https://www.selleckchem.com/products/mrtx0902.html
Cytopathological and histopathological exam results were compatible with a diagnosis of oral candidiasis. Topical antifungal medication led to subsequent regression of the tongue lesions. During asymptomatic period and follow up for 7months, a reduced monthly dose 150mg of secukinumab was administered. Patients undergoing treatment with IL-17 blockers, such as secukinumab, should be carefully monitored in order to avoid oral side effects resulting from the use of this medication. Patients undergoing treatment with IL-17 blockers, such
Like
Comment
Share
